Background: Remdesivir, a drug in use for Ebola it is already tested in clinical trials phase III
Objective: To evaluate any other possible related structures with similar properties that could be used in clinical trials for
Methods: Molecular docking studies, DFT studies, ADMET studies
Result: Saquinavir is a chemical structure with similar and even a better chemical activity that drugs that entered clinical
trials for Covid-19
Conclusion: Saquinavir should be entered the clinical trials for the treatment of the Covid-19 disease, as it has shown
excellent binding affinities to SARS Cov-2 RNA depended polymerase and forms stable complexes with the protein and
could possible inhibited its action.